Neutrophils Exhibit Senescence-Like Behavior in Older Individuals

Key Takeaways

• Aged neutrophils display heightened SASP cytokine levels.
• Reduced glycolysis impairs bacterial killing in older mice.
• Senescence-associated β‑galactosidase increases with host age.
• TNFα blockade restores neutrophil function and infection resistance.
• Potential therapies target senescent-like neutrophil phenotype.

Pulse Analysis

Aging profoundly reshapes innate immunity, and neutrophils—our first line of defense—are no exception. Recent work shows that neutrophils from elderly hosts acquire a senescence‑like signature, characterized by an up‑regulation of pro‑inflammatory SASP molecules such as IL‑10 and TNFα, alongside a marked decline in metabolic pathways essential for pathogen eradication. This shift mirrors classic cellular senescence, yet the cells remain viable, creating a paradox where they persist but function poorly, compromising host defense against common respiratory invaders like Streptococcus pneumoniae.

The mechanistic underpinnings involve a metabolic bottleneck: aged neutrophils fail to activate glycolysis and the downstream mitochondrial ROS burst required for effective bacterial killing. Concurrently, they exhibit elevated senescence‑associated β‑galactosidase activity and reduced apoptosis, prolonging the presence of dysfunctional cells in lung tissue. By profiling transcriptomes of infected mice, researchers pinpointed the SASP, especially TNFα, as a driver of this impaired phenotype. Importantly, pharmacologic inhibition of TNFα not only dampened the senescent‑like profile but also restored antimicrobial activity, translating into higher survival rates for aged animals.

These insights open a therapeutic avenue targeting the senescent‑like state of neutrophils. Modulating SASP signaling, employing senolytic agents, or boosting metabolic pathways could rejuvenate neutrophil function, offering a strategy to mitigate infection susceptibility in older populations. As the global demographic shifts toward greater longevity, interventions that fine‑tune innate immunity will become increasingly vital for public health and healthcare cost containment.